Match!
Hiroki Izumi
Tottori University
20Publications
4H-index
34Citations
Publications 20
Newest
#1Hiroki Izumi (Tottori University)H-Index: 4
#2Akira Yamasaki (Tottori University)H-Index: 15
Last.Shizuka Nishii-Ito (Tottori University)H-Index: 2
view all 14 authors...
Abstract Objectives Zoledronate (ZOL) is usually used for prevention of skeletal-related events in cancer patients with bone metastases. The first administration of ZOL is occasionally associated with development of acute-phase reaction (APR), which is due to activation of γδ T cells. ZOL-related APR was associated with better overall survival (OS) of patients with non-small cell lung cancer (NSCLC) in our previous retrospective study. However, it remains to be clarified whether γδ T cells are m...
#1Hiroki Izumi (Tottori University)H-Index: 4
#2Masahiro Kodani (Tottori University)H-Index: 7
Last.Eiji Shimizu (Tottori University)H-Index: 27
view all 6 authors...
#1Kenichi Takeda (Tottori University)H-Index: 10
#2Akira Yamasaki (Tottori University)H-Index: 15
Last.Haruhiko Makino (Tottori University)H-Index: 6
view all 16 authors...
Background: Chronic obstructive pulmonary disease is a smoking-related disease, and is categorized into the emphysema and airway dominant phenotypes. We examined the relationship between emphysematous changes and epidermal growth factor receptor (EGFR) mutation status in patients with lung adenocarcinoma. Patients and Methods: The medical records for 250 patients with lung adenocarcinoma were retrospectively reviewed. All patients were categorized into the emphysema or non-emphysema group. Resul...
12